BIOTECH CATALYST AI SCANNER — August WK3

The list turned over almost completely this week. Only Karyopharm and Longeveron survive from last week's featured ten; Protagonist, Pyxis and Tyra climb up from the watchlist. That is what happens when a month's worth of "Aug 2026 (Est.)" windows either resolve or expire — the August names either read out, filed, or slipped into September, and a new set of Q3-guided companies moved into the front of the queue behind them.

Which produces the shape of this week's report. Six of the ten featured entries carry a date of "Q3 2026 (Est.)," and every one of those resolves in our feed to a September 30 placeholder. None of them is a published date. Three companies — Spyre, Alumis, Invivyd — have said "Q3" and nothing more precise; two others, Zenas and Clene, have quietly moved past Q3 without our screen noticing. Read the date column as a window and, in two cases below, as an error.

A note on the timing of this run, because it explains most of what follows. The scanner ran Monday morning, August 17. Between August 11 and August 14 roughly a dozen of these companies filed Q2 results. Our balance-sheet feed had not ingested any of them. The result is the largest single batch of cash-field errors we have published a correction for: five in the watchlist alone, all in the same direction — stale quarter, missed financing. Pyxis is wrong for the third consecutive week. FibroBiologics carries a "trading below cash" flag against a cash balance that is actually below its market cap. Every corrected figure below comes from a filing or a press release dated in the last seven days.

One thing did go right. The fact-check layer we built in July finally caught Longeveron — flagged the regulatory setback, cut the score by three points, and dropped the name from #4 to #8 without a human touching it. Two weeks late, but it worked.

Housekeeping: this newsletter winds down at the end of August. Two issues remain, this one included. Deep-dive pieces continue after that.

What We're Tracking:

Corrected This Week — Cash Fields: PYXS ($3.2M / 0.4 months shown; real balance $34.5M plus a $50M July placement, funded into Q2 2027), GUTS ($30.5M / 4.1 months shown; real $47.1M, into early 2027), CLNN ($6.3M shown; real $9.7M), GOSS ($42.9M shown; real $57.0M), FBLG ($14.1M shown; real $3.5M — the error runs the other way), CADL ($268.6M shown; real $201.6M), SCYX ($47.5M shown; real $71.1M)
Corrected This Week — Dates and Facts: ZBIO (screen says August; company guides Q4 2026), LGVN (moved to September on August 12), CLNN (NDA slipped to early Q4), GOSS (the pre-NDA meeting already happened — the September event is the filing), PYXS (data now Fall 2026 / Q4 2026), EVMN (screen omits that this drug's Phase 2b failed in June), IVVD (indication field calls a monoclonal antibody a "vaccine"), SCYX (the completed Phase 1 is the IV formulation, not oral)
"Trading Below Cash" Flags That Do Not Survive the Filings: KPTI ($46M cap / $65M cash — against $441.5M of total liabilities and a going-concern warning), FBLG ($7.1M cap / $3.5M cash — the flag is simply backwards)
Going-Concern Disclosures Among Featured Names: KPTI, LGVN, DWTX
Already Read Out — Detail, Not a Binary: DFTX (Voyage hit on August 12; Panorama is the remaining one), GUTS (midpoint one-year data already reported)
Deeply Oversold (RSI < 30): KPTI (9), GUTS (26), CLNN (27), GOSS (27), MLTX (30)
Overbought Into the Print (RSI > 75): DWTX (89), EVMN (84), FBLG (79), SCYX (77), CADL (77)
Multi-Catalyst (90 days): IVVD, SYRE, SCYX, MLTX

FEATURED

#1. KPTI — Karyopharm Therapeutics Inc.

THE CATALYST
Event: Selinexor (XPORT-MF-034, SENTRY) — sNDA submission seeking accelerated approval in JAK-inhibitor-naïve myelofibrosis
Date: Aug 2026 (Est.)
FDA Status: FTD
BSI: 9.09/10

Karyopharm holds the top rank for a third consecutive week, and for a third consecutive week the reason it holds the top rank is partly an artifact. The company sells XPOVIO (selinexor) commercially in multiple myeloma, has no partner on the myelofibrosis program, withdrew its DLBCL indication, and missed its Phase 3 endometrial cancer primary endpoint on July 30. Q2 numbers are now out, which at least means the balance sheet below is current rather than a March 31 estimate.

Third week, third time we correct the same field. Our screen tags this "Negative EV" and "Deep Value" because $65.1M of cash sits above a $46M market cap. The Q2 filing shows $441.5M of total liabilities, total debt of $299.2M, stockholders' equity of negative $292.9M, and an explicit going-concern warning. There is a $15.8M principal payment due on the senior secured term loan on September 10 and roughly $10.1M of interest due September 30, covered for now by a forbearance agreement that defers payments without waiving defaults if liquidity slips. Enterprise value is firmly positive. "Trading below cash" here means the equity is a thin option on top of a debt stack, not that the downside is padded.

📈 The Setup: Myelofibrosis — a bone-marrow cancer that scars the marrow and swells the spleen — is Incyte's territory in the front line via ruxolitinib (Jakafi), with fedratinib, pacritinib and momelotinib carved into narrower cytopenic and relapsed populations. No combination has ever been approved in the JAK-naïve setting. Selinexor attacks from a different direction: it blocks XPO1, the nuclear export protein that tumour cells use to shuttle tumour-suppressor proteins out of the nucleus where those proteins would otherwise work. In Phase 3 SENTRY (N=353, randomised 2:1, no crossover), adding selinexor to ruxolitinib produced SVR35 — a 35%-or-greater reduction in spleen volume at week 24 — in 49.8% of patients against 28.0% on ruxolitinib alone, with an early survival signal. The symptom-score co-primary was not met. The event this month is a filing, not a decision; the decision is a 2027 problem, and the September debt payments arrive first.

✅ The Edge: Nobody has approved a combination in front-line myelofibrosis, and near-doubling of spleen response on a blinded 2:1 design without crossover is a clean enough result to anchor an accelerated-approval package. Ruxolitinib's own label was built on the same spleen endpoint.
⚠️ The Risk: The missed symptom co-primary gives reviewers a specific objection to hold onto, and accelerated approval on a surrogate invites a confirmatory-trial demand this balance sheet cannot fund. A company with negative equity and a September principal payment has no capacity to absorb a three-month delay, let alone a refuse-to-file.

#2. IVVD — Invivyd Inc.

THE CATALYST
Event: VYD2311 (LIBERTY and DECLARATION) — Phase 3 topline data in COVID-19 prevention
Date: Q3 2026 (Est.)
Additional catalysts: 1 more within 90 days
BSI: 7.48/10

Invivyd is being forced to replace its own product on a clock the FDA set. PEMGARDA (pemivibart), its marketed antibody for pre-exposure prophylaxis in immunocompromised patients, is under a twelve-month advance notice of Emergency Use Authorization termination — which is why everything now rides on the next-generation molecule rather than the one generating revenue. The company works exclusively in antibody prophylaxis against evolving viral threats and has no partner on this program.

Our screen files the indication as "COVID vaccine." It is not one. VYD2311 is a monoclonal antibody — an infusion of pre-made antibodies that works immediately and wanes, rather than training the immune system to make its own. The confusion comes from LIBERTY's design, in which an mRNA vaccine is the comparator arm.

📈 The Setup: Two Phase 3 trials read out together in late Q3, and they answer different questions. DECLARATION is the pivotal one: placebo-controlled, BLA-enabling, testing whether a single intramuscular dose prevents symptomatic COVID at three months. LIBERTY is the positioning one: it compares safety and tolerability head-to-head against an mRNA vaccine, with a short-term endpoint aimed squarely at the myocarditis and pericarditis concerns the FDA has raised about the mRNA class. VYD2311 keeps more than 99% of its structure from pemivibart while carrying sequence changes that delivered roughly 17-fold greater neutralisation potency in vitro against contemporary variants. The competitive problem is not scientific, it is structural: Pfizer and Moderna own the distribution, the pharmacy shelf and the seasonal habit. An antibody has to be meaningfully better tolerated to earn a place beside that, and at a 72-cent share price the market is not paying for the possibility.

✅ The Edge: No other monoclonal antibody is running a late-stage prevention trial in a broad population. If LIBERTY shows a cleaner tolerability profile than an mRNA vaccine on a pre-specified endpoint, Invivyd owns the only regulatory dataset that makes the comparison directly — which is worth more in this policy environment than it would have been two years ago.
⚠️ The Risk: DECLARATION's efficacy signal depends on how many people in the placebo arm actually catch symptomatic COVID. Low event rates or a variant mismatch produce an inconclusive trial rather than a failed one, and inconclusive is the worst outcome for a company whose revenue product is already on a termination notice.

#3. PTGX — Protagonist Therapeutics Inc.

THE CATALYST
Event: Rusfertide (VERIFY) — FDA regulatory decision in polycythemia vera
Date: Aug 2026 — see date note
BSI: 7.01/10

Protagonist took the money and kept the royalty. In April it exercised its U.S. opt-out on rusfertide, converting a 50:50 profit share with Takeda into $200M received immediately, a further $200M due on approval, a $75M milestone, and global royalties in the 14–29% range. Takeda now holds worldwide rights and carries the commercial risk. A separate collaboration with Johnson & Johnson paid a $50M milestone earlier this year. The company's business is peptide chemistry aimed at hematology and immunology; this is the second asset it has monetised without building a salesforce.

Date note: our feed prints "Aug 31, 2026," which is a month-end placeholder, not a published PDUFA day. The FDA granted Priority Review on March 2 with a goal date in August; the specific date has not been disclosed. We flagged this same substitution last week.

📈 The Setup: Polycythemia vera is a blood cancer of red-cell overproduction, and the front-line answer is still to physically drain blood — therapeutic phlebotomy — supported by hydroxyurea, with ropeginterferon (Besremi) and ruxolitinib (Jakafi) taking patients who fail or cannot tolerate it. Rusfertide is a hepcidin mimetic: a synthetic peptide copying the hormone that rations how much iron reaches the marrow, throttling red-cell production at the supply line rather than suppressing the marrow broadly. In Phase 3 VERIFY (N=293 phlebotomy-dependent patients on standard care), 76.9% met the clinical-response endpoint against 32.9% on placebo, mean phlebotomies fell from 1.8 to 0.5, and haematocrit stayed under 45% in 62.6% versus 14.4%. Patient-reported fatigue improved on pre-specified measures. It is first-in-class, priority-reviewed, and carries Breakthrough, Orphan and Fast Track designations. The trade is not the science — it is a $400M-plus cash event landing inside a two-week window.

✅ The Edge: No other hepcidin mimetic is in late-stage development for this disease, and the mechanism sits upstream of everything approved — it can be added to Jakafi or Besremi rather than displacing them. Approval also releases $275M of contracted payments into a company already holding $620M.
⚠️ The Risk: Priority Review sets a goal date, not an outcome. The FDA has thin precedent for patient-reported outcome endpoints in polycythemia vera, and the plausible bad case is not rejection but a narrowed label restricted to the phlebotomy-dependent population — which would leave Takeda selling into a slice of the market the stock is not currently priced for.

#4. URGN — UroGen Pharma Ltd.

THE CATALYST
Event: UGN-103 (UTOPIA) — NDA submission in low-grade intermediate-risk non-muscle-invasive bladder cancer
Date: Q3 2026 (Est.)
BSI: 6.98/10

UroGen already sells the drug this one is meant to replace, and it is selling well. ZUSDURI (mitomycin intravesical solution) posted $50.4M of revenue in Q2, up 73% quarter over quarter — an approved product on a genuine commercial ramp, which is a rare thing on this list. The company builds sustained-release bladder therapies around its RTGel platform. It is incorporated in Israel with U.S. operations in New Jersey, and a February refinancing with Pharmakon supplied non-dilutive capital ahead of the launch spend.

📈 The Setup: Recurrent low-grade intermediate-risk bladder cancer is managed by repeatedly cutting tumours out under anaesthesia — a transurethral resection, or TURBT — and then doing it again when the disease returns. ZUSDURI became the first non-surgical alternative in June 2025. UGN-103 is the second-generation formulation of the same idea: mitomycin suspended in RTGel, a reverse-thermal hydrogel that is liquid when instilled and thickens at body temperature so the drug stays in contact with the bladder wall. In Phase 3 UTOPIA it produced a 94.5% six-month duration of response against 91.9% for ZUSDURI in its pivotal trial, and a 77.8% three-month complete response against 79.6% — the same eligibility criteria in both. That near-identity is the whole strategy and the whole vulnerability: the filing rests on demonstrating formulation and manufacturing equivalence, not superiority. The broader NMIBC field — cretostimogene, Anktiva, programs at J&J and Pfizer — is fighting over high-grade disease and does not touch this population.

✅ The Edge: UroGen is filing into a market it created and currently owns outright, with the commercial infrastructure, urologist relationships and reimbursement pathway already built for the predecessor product. The incremental cost of launching UGN-103 is close to zero, and the patent runway extends into 2041.
⚠️ The Risk: When the efficacy case is "it matches the drug we already sell," the FDA's attention moves entirely to chemistry, manufacturing and stability data on a changed formulation. An information request or an advisory committee on those grounds delays approval past the ZUSDURI precedent without anything being wrong with the drug — and cannibalisation means the upside was always incremental.

#5. SYRE — Spyre Therapeutics Inc.

THE CATALYST
Event: SPY072 (SKYWAY-RD basket study) — Phase 2 proof-of-concept topline data in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis
Date: Q3 2026 (Est.)
Additional catalysts: 1 more within 90 days
BSI: 6.76/10

Spyre raised $435M in April against a balance sheet that already stretched past 2029, which tells you the company expects to run several expensive answers in parallel rather than wait for one. It builds long-acting antibodies for immune-mediated disease, with an inflammatory bowel programme (SKYLINE) and a rheumatology programme (SKYWAY) advancing at once. No partnerships are disclosed and none are needed. Enrolment across the SKYWAY basket completed in under nine months, and the RA readout was pulled forward to Q3 in March.

📈 The Setup: Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis are run by TNF inhibitors (adalimumab, etanercept), IL-17 inhibitors (secukinumab, ixekizumab) and JAK inhibitors (upadacitinib, tofacitinib) — a mature field where the efficacy bar is well established and the differentiation fights are about convenience and safety. SPY072 blocks TL1A, a cytokine that sits upstream of several inflammatory pathways, and is Fc-engineered for a long half-life that could support dosing every three or six months instead of weekly or fortnightly. Nobody has tested any anti-TL1A antibody in these three diseases before; the mechanism's clinical validation to date comes from inflammatory bowel disease, where tulisokibart and afimkibart are in Phase 3. What lands in Q3 is the RA sub-study only — PsA and axSpA follow in Q4. Read it as a first look at whether TL1A does anything in joints, not as a verdict on the franchise.

✅ The Edge: Dosing intervals of three to six months would be unlike anything in rheumatology, where the practical failure mode is patients drifting off a fortnightly injection. And the read-through runs both ways: Spyre is testing a mechanism in joints that its own IBD programme is testing in gut, on a balance sheet that funds both to conclusion.
⚠️ The Risk: TL1A biology is validated in inflammatory bowel disease and nowhere else — the preclinical support here is a rat arthritis model. A twelve-week proof-of-concept in a basket design, with heterogeneous populations split across three indications, is exactly the format in which a real-but-modest signal gets buried in subgroup noise against a placebo-adjusted benchmark set by TNF inhibitors.

#6. ALMS — Alumis Inc.

THE CATALYST
Event: Envudeucitinib (ESK-001, LUMUS) — Phase 2b topline data in systemic lupus erythematosus
Date: Q3 2026 (Est.)
BSI: 6.74/10

A week ago Alumis published the psoriasis data that makes this readout matter. On August 10 it reported 48-week Phase 3 results showing envudeucitinib delivering the highest PASI 100 rate — complete skin clearance — of any oral therapy in plaque psoriasis, at 54%. That programme is heading for an NDA. The lupus trial is the test of whether the same molecule travels into a harder disease. The company came together through a 2025 all-stock merger with ACELYRIN and licensed Japanese dermatology rights to Kaken for $40M in upfront and near-term payments.

📈 The Setup: Systemic lupus is treated with injectables — belimumab (Benlysta), which strips out a B-cell survival factor, and anifrolumab (Saphnelo), which blocks the type I interferon receptor — and there is no high-efficacy oral option. Envudeucitinib is an allosteric TYK2 inhibitor: it binds the enzyme's regulatory pseudokinase domain rather than its active site, which is what buys selectivity over the broader JAK family and the laboratory abnormalities that come with it. Blocking TYK2 shuts down IL-12, IL-23 and type I interferon signalling at once, and interferon is the pathway that drives lupus. LUMUS enrolled 408 patients across multiple doses against a BICLA response endpoint at week 48 — a composite that requires improvement across every affected organ system with no worsening anywhere, measured at a timepoint most lupus Phase 2 trials do not reach. The bar Alumis set for itself is unusually high, deliberately.

✅ The Edge: Reading out a 48-week BICLA result from a 408-patient trial gives Alumis something most Phase 2b lupus programmes cannot offer a partner or a regulator: durability evidence at the point of proof-of-concept. Paired with a psoriasis Phase 3 already showing best-in-class oral clearance, it converts a single molecule into a franchise argument across interferon-driven disease.
⚠️ The Risk: Lupus is where good drugs go to produce ambiguous composites. Psoriasis efficacy has repeatedly failed to translate — the disease is heterogeneous, background steroid tapering distorts the comparison, and BICLA is unforgiving. A 48-week endpoint also means eleven months of retention across a global multi-arm trial, and dropout asymmetry alone can decide the result.

#7. DFTX — Definium Therapeutics Inc.

THE CATALYST
Event: DT120 ODT (lysergide tartrate, Panorama) — Phase 3 topline data in generalized anxiety disorder
Date: Q3 2026 (Est.) — company guides September
BSI: 6.70/10

Five days before this scan ran, the company reported a positive Phase 3. On August 12 Definium — the former MindMed, renamed in January, with MM120 renamed DT120 — announced that Voyage met its primary endpoint in generalized anxiety disorder: a least-squares mean reduction of 11.6 points on the Hamilton Anxiety Rating Scale against 6.2 for placebo at week 12, from a single 100 µg dose. That followed positive Emerge results in major depressive disorder in June. Panorama, the second GAD Phase 3, reports in September. Our screen's own cash guard flagged the balance sheet as unverified because the runway field exceeded its sanity threshold; the figure checks out at roughly $1.1B, funded into 2028.

One data note: the trial results our deep-dive attached to Voyage — a 43%-versus-16% responder rate at p=0.0222 in 214 patients — are Phase 2b figures, not the August 12 topline. The numbers above are the ones the company published.

📈 The Setup: Generalized anxiety disorder is managed with SSRIs, SNRIs and short-course benzodiazepines — daily medication, weeks to onset, and discontinuation problems at the back end. DT120 is an orally disintegrating tablet of lysergide, an agonist at the 5-HT2A serotonin receptor, given once under supervision on the theory that a single dose drives a durable change in neural plasticity rather than requiring continuous suppression. No classic psychedelic has ever been approved; Compass Pathways is the nearest comparator, still working in treatment-resistant depression. What changes the character of this name is that Voyage already answered the central question. Panorama is a confirmatory replication into a stock that has already absorbed the good news, which makes the payoff asymmetric in the unhelpful direction: a hit is largely expected, a miss reopens everything.

✅ The Edge: Two positive Phase 3 readouts across two separate indications in three months, on the same molecule and the same single-dose model. Nobody else in the psychedelic field has that, and it is the difference between a mechanism that works and a mechanism that worked once.
⚠️ The Risk: The FDA has not approved a supervised single-dose psychedelic, and the Lykos MDMA complete response letter showed the agency's concerns run to psychological-support requirements, functional unblinding and long-term safety rather than effect size. Panorama uses a 50 µg control arm; if placebo response drifts up or durability comes in shorter than Voyage, a replication failure would land on a $5.7B market cap that is already pricing the win.

#8. LGVN — Longeveron Inc.

THE CATALYST
Event: Laromestrocel (lomecel-B, ELPIS II) — Phase 2b topline data in hypoplastic left heart syndrome
Date: September 2026 — our screen still shows August; the company moved it on August 12
FDA Status: FTD, ODD
BSI: 6.52/10

This is the third week we have written about Longeveron and the first week our own machinery got there first. The fact-check layer flagged the regulatory setback, cut the AI score by three full points, tagged the name "Regulatory Setback" and dropped it from what would have been a top-four rank to #8 — automatically. For two weeks running it read the company's "constructive Type C meeting" headline and missed the substance underneath. This week it read the substance. The company develops allogeneic mesenchymal stem cell therapies for rare paediatric conditions, is funded partly by NHLBI grants, and raised a private placement led by Coastlands Capital in March.

The substance, restated because it still governs the trade. In May the FDA told Longeveron that right ventricular ejection fraction is not sufficient to demonstrate efficacy, and that it no longer considers ELPIS II a pivotal trial. The agency said it would revisit once results exist. Separately, the Q2 10-Q discloses substantial doubt about the company's ability to continue as a going concern — $10.1M of cash funding operations into Q4 2026, against a forecast that does not cover twelve months of commitments. Both things are true at once, and the September readout arrives before either is resolved.

📈 The Setup: Hypoplastic left heart syndrome means a child is born with half a working heart, and the standard of care is three staged surgeries — Norwood, Glenn, Fontan — that reroute the circulation without fixing it. Transplant risk stays high afterward and there is no approved drug or cell therapy of any kind. Laromestrocel is an off-the-shelf mesenchymal stem cell product from young healthy donor marrow, injected into the heart during the second-stage operation, intended to promote vessel growth and damp inflammation in a ventricle being asked to do work it was not built for. ELPIS I showed 100% transplant-free survival to age five in a small single-arm cohort. ELPIS II randomises 40 patients across 12 paediatric cardiac centres against a composite of survival, hospitalisation and RVEF change — and RVEF is the component the FDA has already said will not carry an approval.

✅ The Edge: It is the only off-the-shelf cell therapy in a randomised trial in this disease — the competing approaches, autologous cord-blood cells at Mayo and cardiac progenitor cells in APOLLON, all require harvesting from the patient. In a condition affecting a few hundred U.S. births a year, an allogeneic product is the only version that is commercially manufacturable at all.
⚠️ The Risk: Forty patients, a composite endpoint whose primary component the FDA has explicitly rejected, and a going-concern warning that expires around the same time as the cash. Even a clean result buys a conversation about a new pivotal trial, not a filing — and financing that trial from a $24M market cap means dilution on whatever terms are available.

#9. ZBIO — Zenas BioPharma Inc.

THE CATALYST
Event: Obexelimab (SunStone) — Phase 2 topline data in systemic lupus erythematosus
Date: Q4 2026 — our screen shows August 2026; the company guides Q4
BSI: 6.43/10

The date on this entry is wrong by a quarter, and it is the reason the name is ranked where it is. Our feed pulled a 2025 statement guiding to "mid-2026" and resolved it to a month-end placeholder thirteen days out. Zenas confirmed at Q2 that enrolment is complete and topline results — overall and biomarker populations — come in Q4 2026. Nothing is imminent. Rank it as a Q4 name that our screen pulled forward, and note that the internal fact-check assigned this thesis its second-lowest confidence score of the week for exactly this reason. The company works in autoimmune disease, is funded through a Royalty Pharma agreement, a $250M Pharmakon debt facility and roughly $374M of 2026 equity and convertible issuance, and licensed additional immune assets from InnoCare.

📈 The Setup: Lupus again — belimumab and anifrolumab approved, litifilimab, ianalumab and deucravacitinib in the pipeline behind them, and a long history of B-cell drugs failing on composite endpoints. Obexelimab is a humanised anti-CD19 antibody engineered to also engage FcγRIIb, the inhibitory receptor B cells use to switch themselves off. The result is that it silences B cells rather than killing them, which in principle avoids the prolonged depletion and infection risk of rituximab-style approaches. The real support for this readout is not the prior lupus proof-of-concept work but Phase 3 INDIGO, where the same molecule cut flare risk by 56% in IgG4-related disease and is heading to a BLA. That is mechanism validation on the identical construct — in a different disease, on a different endpoint, in a far more homogeneous population.

✅ The Edge: A positive Phase 3 in hand on the same molecule means the SLE readout is testing whether the disease responds, not whether the drug engages its target. And with $674M funding operations into 2029, Zenas can take a mediocre Phase 2 and run the confirmatory work anyway — most companies at this stage cannot.
⚠️ The Risk: Anti-CD19 approaches have run into lupus before and produced marginal results, because the disease's heterogeneity and the BICLA composite together punish drugs with real but partial effects. IgG4-related disease is a cleaner, more B-cell-driven target than lupus; the read-through is weaker than it looks. And the readout is a quarter further out than any date in our table suggests.

#10. DWTX — Dogwood Therapeutics Inc.

THE CATALYST
Event: Halneuron (HALT-CINP) — Phase 2b topline data in chemotherapy-induced neuropathic pain
Date: Q3 2026 (Est.) — company guides fall 2026
FDA Status: Fast Track
BSI: 5.66/10

A stock up 56% in three weeks on almost no volume, into a readout the company can just barely afford to reach. Dogwood develops non-opioid analgesics for cancer-related pain. It licensed its antiviral candidates to PRIDCor in April to concentrate on Halneuron, raised equity in January to reach this data, and its filings disclose substantial doubt about continuing as a going concern beyond Q4 2026 without further capital. Cash on hand is $9.6M — enough for the readout, not for what comes after it.

Flag note: our screen tags this "Regulatory Setback." There has been no regulatory setback. The tag is triggered by the going-concern disclosure, which is a financial event, and the label is misleading as printed.

📈 The Setup: Chemotherapy-induced neuropathic pain is treated with duloxetine and pregabalin — drugs borrowed from other indications that work moderately and are abandoned by 20–40% of patients in trials because of sedation, weight gain and dizziness. Halneuron blocks NaV1.7, the voltage-gated sodium channel that carries pain signals from peripheral nerves, with enough selectivity to avoid the off-target effects that sank earlier sodium-channel programmes. It has been given to more than 700 patients across prior studies. The Phase 2b randomised roughly 217 patients against placebo with change in weekly average daily pain score at week four as the primary endpoint, and the striking operational number so far is a dropout rate around 4.4% — a fifth of what the approved comparators produce. An unblinded interim review of the first completers reportedly showed separation from placebo. That is the case for the 56% move; it is also secondhand, and interim looks at partial data are the least reliable signal in clinical development.

✅ The Edge: Tolerability is the actual clinical problem in this indication — patients stop taking duloxetine and pregabalin, which is why neither controls the disease in practice. A drug that holds 95% of patients for four weeks has an argument that does not depend on beating them on raw effect size, and no other NaV1.7 candidate is in late-stage development here.
⚠️ The Risk: RSI 89 on 0.09x volume means this has moved on a thin book and almost none of the buying will be there when the print lands. A four-week endpoint in a refractory population is a narrow window to demonstrate a durable effect, and with $9.6M of cash and a going-concern flag, even a positive Phase 2b leads directly to a financing before the Phase 3 that positive data would require.

WATCHLIST

#11. PYXS — Pyxis Oncology Inc. [Oncology / ADC]

Price: $3.01 | Cap: $251M | Cash: $34.5M at Jun 30 + ~$50M July placement | RSI: 52 | Momentum: +27.5%
Micvotabart pelidotin (MICVO, PYX-201-101) — Phase 1/2 interim data in head and neck squamous cell carcinoma (Fall 2026 / Q4 2026)
FTD, ODD
BSI: 6.81/10

The Intel: Third consecutive week of a broken cash field — our screen shows $3.2M and 0.37 months of runway. The real position is $34.5M at June 30 plus roughly $50M of upfront proceeds from a July 2 private placement, funding the company into Q2 2027, with up to $64M more if the accompanying warrants are exercised. The date is also wrong: monotherapy Phase 1 data is guided to Fall 2026 and the combination dataset to Q4, not August. MICVO is an antibody-drug conjugate aimed at extra domain B fibronectin, a protein found in tumour stroma rather than on cancer cells themselves — it delivers a microtubule-poisoning payload into the tissue scaffold around the tumour. December data showed 46% confirmed response as monotherapy and 71% in combination with pembrolizumab (KEYTRUDA) in recurrent/metastatic head and neck cancer. Small cohorts, but genuinely differentiated targeting.

#12. CADL — Candel Therapeutics Inc. [Oncology / Viral Immunotherapy]

Price: $11.72 | Cap: $897M | Cash: $201.6M (Jun 30) | RSI: 77 | Momentum: +15.1%
Aglatimagene besadenovec (CAN-2409, ULYSSES) — Phase 3 data presentation at ASTRO in localized prostate cancer (Sep 29, 2026)
FTD, RMAT
BSI: 6.75/10

The Intel: Cash corrected: $201.6M, funding into Q1 2028, not the $268.6M our feed carried. Understand what the September event actually is — Candel is presenting an AI-enabled digital pathology analysis of paired biopsies taken at baseline and two years post-radiation, examining immune-cell infiltration in the tumour microenvironment. It is mechanistic supporting work, not new efficacy data. The efficacy readout already happened: the Phase 3 showed a 30% improvement in disease-free survival when CAN-2409 was added to curative-intent radiotherapy. CAN-2409 injects an adenovirus carrying a herpes thymidine kinase gene directly into the tumour, so that a subsequent prodrug is converted into a toxin inside dividing cells, killing them in a way that also exposes tumour antigens to the immune system. The BLA is the real catalyst, and it is a Q4 2026 event. RSI 77 into a conference abstract is the wrong risk to be taking.

#13. EVMN — Evommune Inc. [Immunology / Dermatology]

Price: $14.65 | Cap: $532M | Cash: $191.8M | RSI: 84 | Momentum: +20.7%
EVO756 — Phase 2b topline data in moderate-to-severe atopic dermatitis (September 2026)
BSI: 6.74/10

The Intel: A material omission in our screen, and the most important correction in the watchlist. On June 29 Evommune reported that EVO756 failed its Phase 2b trial in chronic spontaneous urticaria — no efficacy at week 12, development in that indication discontinued, ending what had been framed as a challenge to Novartis's omalizumab. Our overview describes only "recent phase 1 data confirming safety and target engagement," which is true and radically incomplete. EVO756 is an oral antagonist of MRGPRX2, a mast-cell receptor that triggers itch and inflammation without going through the classical IgE allergy pathway. The September readout in atopic dermatitis is a ~120-patient dose-ranging study, and it is now the second attempt to show this mechanism does anything clinically. RSI 84 heading into it, with a failed Phase 2b already on the record for the same molecule.

#14. GUTS — Fractyl Health, Inc. [Metabolic / Device]

Price: $0.68 | Cap: $108M | Cash: $47.1M (Jun 30) | RSI: 26 | Momentum: -16.0%
Revita (REMAIN-1) — Phase 3 pivotal cohort topline in post-GLP-1 weight maintenance (early Q4 2026)
BSI: 6.68/10

The Intel: Two corrections. Cash is $47.1M funding into early 2027, not $30.5M and 4.1 months — the "Cash Crunch" flag does not hold. And the Q3 catalyst our screen is pointing at has already occurred: Fractyl reported one-year randomised midpoint-cohort data showing Revita patients retained over 80% of their GLP-1-induced weight loss against 46% for sham, with no patient restarting a GLP-1. The event that remains is the pivotal cohort's six-month topline in early Q4, followed by a De Novo submission late in the quarter. Revita is not a drug — it is a single endoscopic procedure that ablates and resurfaces the duodenal lining to reset nutrient signalling. The thesis is that the hardest problem in obesity medicine is now what happens after patients stop taking semaglutide or tirzepatide, and a one-time procedure is the only answer being tested at scale. At $0.68 a share and RSI 26, the market is pricing the financing risk ahead of the data.

#15. CLNN — Clene Inc. [Neurology / ALS]

Price: $4.14 | Cap: $53M | Cash: $9.7M (Jun 30) | RSI: 27 | Momentum: -30.1%
CNM-Au8 — NDA submission under accelerated approval in amyotrophic lateral sclerosis (early Q4 2026)
BSI: 6.67/10

The Intel: Corrected on both fields: cash is $9.7M, not $6.3M, extended through late Q4 2026 by a $7.0M registered direct offering and the pushing of $11.5M of convertible debt maturities out to August 2027. The filing itself has slipped from Q3 to early Q4. Clene's asset is a suspension of gold nanocrystals that acts catalytically inside neurons to boost mitochondrial energy production — a bioenergetic approach rather than targeting a specific misfolded protein. In May the FDA said the proposed data package may be capable of supporting review under the accelerated approval pathway, which is the sentence the entire equity rests on. Supporting evidence is biomarker-driven: patients whose neurofilament light chain fell or stabilised survived longer. A confirmatory Phase 3 is planned for later this year. A 12.8M share float and $9.7M of cash against a filing that must be financed — the leverage cuts hard in both directions.

#16. SCYX — SCYNEXIS Inc. [Anti-infectives]

Price: $5.18 | Cap: $52M | Cash: $71.1M (Jun 30) | RSI: 77 | Momentum: +21.3%
SCY-247 — Phase 1 topline data in invasive candidiasis (Q3 2026)
BSI: 6.65/10

The Intel: Cash corrected upward to $71.1M with runway into 2029 — our feed showed $47.5M. Also: the Phase 1 that completed dosing is the intravenous formulation, not the oral one our overview describes. SCY-247 is a second-generation glucan synthase inhibitor, blocking the enzyme that builds fungal cell walls, designed to retain activity against Candida strains that have become resistant to echinocandins — a genuinely growing hospital problem. A second Phase 1 readout also lands in Q3 for SCY-770, an AMPK activator in polycystic kidney disease, with a Phase 2 planned for Q4. Two first-in-human datasets in one quarter from a company whose market cap sits below its cash balance. But these are Phase 1 safety and pharmacokinetic studies — they establish that dosing is feasible, nothing about efficacy, and RSI 77 is a lot of anticipation for that.

#17. GOSS — Gossamer Bio Inc. [Pulmonary]

Price: $0.15 | Cap: $75M | Cash: $57.0M (Jun 30) | RSI: 27 | Momentum: -9.4%
Seralutinib (PROSERA) — NDA submission in pulmonary arterial hypertension (September 2026)
BSI: 6.62/10

The Intel: Our screen has the wrong event. It lists a pre-NDA Type B meeting scheduled for September — that meeting already happened, and Gossamer announced the outcome on July 27. The September event is the NDA filing itself. The company also reacquired worldwide rights to seralutinib from Chiesi, shareholders approved a convertible note exchange, and a reverse split was authorised. Cash is $57.0M, not the $42.9M shown. What makes this unusual: PROSERA missed its primary endpoint in February — a placebo-adjusted six-minute walk distance improvement of 13.3 metres at p=0.032 against a pre-specified threshold of 0.025 — and the FDA has nonetheless agreed to a filing supported by that trial plus confirmatory evidence from Phase 2 TORREY. Seralutinib is an inhaled kinase inhibitor hitting PDGFR, CSF1R and c-KIT to reverse vascular remodelling in the lung. If accepted, a decision could come in Q3 2027. A statistically missed Phase 3 that becomes a filing is rare, and it is entirely a function of the FDA's current posture on serious disease.

#18. FBLG — FibroBiologics Inc. [Cell Therapy / Wound Care]

Price: $1.06 | Cap: $7.1M | Cash: $3.5M (Jun 30) | RSI: 79 | Momentum: +26.9%
CYWC628 — Phase 1/2 six-week interim safety and efficacy data in diabetic foot ulcers (2H 2026)
BSI: 6.56/10

The Intel: The "Negative EV" flag on this name is backwards. Our feed carries $14.1M of cash against a $7.1M market cap; the Q2 filing shows $3,515 thousand — $3.5M — alongside an explicit going-concern disclosure. The company has been raising in small increments all year: SEPA shares in March, a registered offering in April, an ATM programme, and a June private placement of pre-funded warrants. CYWC628 delivers donor-derived fibroblasts — the cells that build connective tissue — to secrete growth factors and lay down extracellular matrix in a chronic wound. The Phase 1/2 is running in Australia, enrolment has been slower than the company anticipated, six-week interim data is guided to the second half of the year and final twelve-week data to Q4. A 6.7M share float and RSI 79 explain the price action better than the science does.

#19. MLTX — MoonLake Immunotherapeutics [Immunology / Dermatology]

Price: $16.47 | Cap: $1.40B | Cash: $461M | RSI: 30 | Momentum: -16.3%
Sonelokimab (VELA-1 / VELA-2) — BLA submission in hidradenitis suppurativa (end of September 2026)
BSI: 6.53/10

The Intel: The pre-BLA process is finished, no further FDA meetings are scheduled, and MoonLake intends to file at the end of September with a Priority Review request; acceptance and PDUFA clarity are expected by end-November. The 52-week VELA data are the strongest in the disease — 67.2% of patients reaching HiSCR75 and 33.1% reaching HiSCR100 across both trials at one year, improving from week 16 rather than fading. Sonelokimab is a Nanobody, a compact antibody fragment roughly a tenth the size of a conventional monoclonal, which blocks IL-17A and IL-17F and penetrates inflamed tissue more readily than full-size antibodies. Hidradenitis suppurativa is an inflammatory skin disease that produces painful abscesses and tunnels under the skin; the approved options are adalimumab and secukinumab, and neither works well. The stock is down 73% from its 52-week high and oversold at RSI 30 into a filing, which is a strange combination.

#20. TYRA — Tyra Biosciences Inc. [Oncology / Precision Medicine]

Price: $25.29 | Cap: $1.51B | Cash: $340M | RSI: 30 | Momentum: -21.3%
Dabogratinib (TYRA-300, SURF302) — Phase 2 initial three-month complete response data in FGFR3-altered low-grade intermediate-risk non-muscle-invasive bladder cancer (Aug 2026)
BSI: 6.32/10

The Intel: Featured at #10 last week, now at #20 — the score moved up slightly while the field around it improved more. The setup is unchanged and the data is due this month. Low-grade intermediate-risk bladder cancer is managed by repeat surgical resection under anaesthesia, with no targeted oral option; the approved FGFR drug, erdafitinib, hits FGFR1 through 4 and carries the hyperphosphataemia and mouth-ulcer toxicity that comes with that, tolerable only in advanced disease. Dabogratinib is engineered to hit FGFR3 selectively, which is what could make an oral drug viable in patients who are not sick enough to accept the alternative. SURF302 is open-label, randomising up to 90 patients between 50mg and 60mg daily, with over 20 enrolled as of Q1. Note the overlap with UroGen at #4 — same disease, entirely different approach, and UroGen already has an approved product in it.

The Strategist's Take

The interesting thing about this week is what fixed itself and what did not. Longeveron got caught — automatically, by the verification layer, which docked three points and moved it from a top-four rank to eighth without anyone intervening. That is the first time it has worked on the specific failure mode it was built for, after two consecutive weeks of reading a "constructive Type C meeting" headline and stopping there. Worth stating plainly: the layer is now catching regulatory narrative that has been deliberately buried under a favourable adjective, which was the hard part.

The balance sheets are a different story, and this week they were worse than usual for a boring reason. The scan ran on August 17; a dozen of these companies filed Q2 between the 11th and the 14th; our cash feed had ingested none of it. Seven corrections, five of them in the watchlist, all traceable to the same lag. But the direction of the errors matters more than the count. Pyxis has now shown a fabricated cash crisis for three straight weeks against a company funded into Q2 2027. Fractyl carried a "Cash Crunch" flag on a balance sheet with $47.1M and runway into 2027. And FibroBiologics ran the error backwards — flagged as trading below cash when its actual $3.5M sits well under a $7.1M market cap, with a going-concern warning attached. A screen that is wrong in both directions on the same field in the same week is not a screen you should be reading the flags off. Read the filings.

Underneath the corrections, the genuinely asymmetric names are the two where something has already been proven. Protagonist at BSI 6.01 is the cleanest event on the list: a first-in-class drug with a 77%-versus-33% Phase 3, priority review, and $275M of contracted payments that release on approval — held by a company with $620M in the bank that has already sold the commercial risk to Takeda. It is the only entry here where a positive outcome is a cash event rather than a narrative one. Karyopharm is the opposite kind of asymmetry: the myelofibrosis data is real and the filing is real, but so are $441.5M of liabilities, negative equity and a September 10 principal payment. It sits at #1 because the model likes cheap, and it is cheap because the capital structure might take the company out before the FDA ever rules. Both facts are the same fact.

Be careful where the anticipation has already been paid for. Dogwood is up 56% in three weeks on 0.09x volume with RSI 89, heading into a four-week pain endpoint, with $9.6M of cash and a going-concern flag — the good outcome is priced and the financing follows either way. Evommune comes in at RSI 84 on a molecule whose Phase 2b already failed in a different indication in June, which our own screen did not mention. Candel at RSI 77 is running into a conference abstract, not a data event. And Definium, at a $5.7B market cap, has the strongest recent evidence on this list and the least left to prove — Voyage hit on August 12, so September's Panorama is a replication into a stock that has already taken the win. Confirmatory trials are where you find out whether the first result was the drug or the trial.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.3 | Generated: 2026-08-17T09:53:13